BioSpace News Archive

Lipocine Inc. announced that its management will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners.

OnQuality Pharmaceuticals (“OnQuality”) today announced that regulatory authorities in China and India have approved Part 2 of the NOVA-II Phase 2 clinical trial, evaluating OQL011, a topical ointment for the management of Hand-Foot Skin Reaction (HFSR) in cancer patients receiving vascular endothelial growth factor receptor (VEGFR) inhibitor(s) (VEGFRi) as part of their anti-cancer treatment.

Conformal Medical, Inc. announced the publication of the peer-reviewed article, “Foam-based Left Atrial Appendage Closure Device: Evaluation in a Chronic Canine Model,” in the Journal of the Society for Cardiovascular Angiography and Interventions.

MAIA Biotechnology, Inc. (NYSE American: MAIA ) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences as follows.

Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round.

bluebird bio, Inc . (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 7:30AM PT.

OncoResponse announced that Clifford Stocks, Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11 a.m. PST.

ElevateBio to Present at the 41 st Annual J.P. Morgan Healthcare Conference.

AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it raised $20 million in Series B financing.

Xenetic Biosciences, Inc. today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 10:00 AM ET.